• In recent weeks Ameresco reported quarterly results showing 13.8% year-on-year revenue growth and a roughly 20% increase in awarded backlog to almost US$2.80 billion, even as it missed full-year EBITDA guidance and analysts’ EPS estimates.
• At the same time, a series of insider option exercises and sales plus the launch of the Neogenyx Fuels renewable natural gas joint venture in Nebraska have raised fresh questions about how Ameresco is balancing growth investments with near-term profitability.
• We’ll now examine how Ameresco’s strong backlog growth but weaker profitability guidance may influence its pre-existing investment narrative and outlook.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Ameresco Investment Narrative Recap

To own Ameresco, you need to be comfortable with a company trading near-term margins for a growing, long-duration clean energy project base. The immediate catalyst remains converting its nearly US$2.80 billion awarded backlog into revenue and cash flow, while the biggest near-term risk is execution and profitability on these capital intensive projects. The latest results, with strong backlog growth but weaker EBITDA and EPS, reinforce rather than materially change that balance of opportunity and risk.

The Neogenyx Fuels joint venture stands out here. By contributing its biofuels business and securing US$400 million of partner capital, Ameresco is trying to scale renewable natural gas while freeing balance sheet capacity for other grid and infrastructure work. This JV ties directly into the backlog story, since projects like the Nebraska RNG facility sit at the intersection of long term contracted revenue potential and the same construction, financing, and margin execution risks already worrying investors.

Yet investors also need to be aware that if higher project costs persist and interest expenses stay elevated, Ameresco’s thin net margins could come under even more pressure...

Ameresco's narrative projects $2.5 billion revenue and $103.5 million earnings by 2029. This implies 9.4% yearly revenue growth and about a $59 million earnings increase from $44.2 million today.

Uncover how Ameresco's forecasts yield a $42.60 fair value, a 34% upside to its current price.

Exploring Other Perspectives

Compared with consensus, the most optimistic analysts were assuming Ameresco could lift earnings to about US$130.8 million on roughly US$2.8 billion of revenue, helped by faster backlog conversion and higher margin assets, so this earnings miss and renewed margin concerns may prompt you to question whether that upgraded trajectory still holds or needs a rethink.

Explore 4 other fair value estimates on Ameresco - why the stock might be worth as much as 95% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ameresco research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Ameresco research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ameresco's overall financial health at a glance.

No Opportunity In Ameresco?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.